Skip to main content
Premium Trial:

Request an Annual Quote

GNI, Aukland UniServices to Map Breast Cancer, Melanoma Gene Networks

NEW YORK (GenomeWeb News) — GNI and Auckland UniServices today today said they will work together to map gene regulatory networks for melanoma and breast cancer.
According to the partners, the effort will also study how the networks are affected as patients respond to various anti-cancer drugs. GNI and UniServices will co-own the intellectual property resulting from the three-year collaboration and GNI will lead the effort to commercialize it, the companies said.
GNI, a Japanese biopharmaceutical company, will provide its technology and reagents to produce the gene networks. In addition, some data analysis will be done at GNI's Systems Pharmacology Research Institute in Fukuoka.
The collaboration is supported by grants from New Zealand Health Research Council's International Investment Opportunities Fund and New Zealand's Breast Cancer Research Trust.
Auckland UniServices is the commercial arm of the University of Aukland.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.